Chronic hepatitis B: Back to the future with HBsAg

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 6, 2009, Pages 633-636

  Moucari, Rami ^a   Lada, Olivier ^a   Marcellin, Patrick ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COVALENTLY CLOSED CIRCULAR DNA; DNA; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; PEGINTERFERON ALPHA; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; BIOLOGICAL MARKER; INTERFERON; MACROGOL DERIVATIVE; NUCLEOSIDE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIGEN DETECTION; DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; NONHUMAN; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; SEROCONVERSION; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS LOAD; VIRUS PARTICLE; BLOOD; DRUG COMBINATION; DRUG EFFECT; IMMUNOLOGY; ISOLATION AND PURIFICATION; MULTICENTER STUDY; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; LAMIVUDINE; MULTICENTER STUDIES AS TOPIC; NUCLEOSIDES; POLYETHYLENE GLYCOLS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 70350457819     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.57     Document Type: Editorial

References (27)

1. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N. Engl. J. Med. 350, 118-1129 (2004).
2. Liang TJ. Hepatitis B: the virus and disease. Hepatology 49, S13-S21 (2009).
3. Werle-Lapostolle B, Bowden S, Locarnini S et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126, 1750-1758 (2004). (Pubitemid 38736340)
4. Wursthorn K, Lutgehetmann M, Dandri M et al. Peginterferon α-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 44, 675-684 (2006). (Pubitemid 44433724)
5. Volz T, Lutgehetmann M, Wachtler P et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology 133, 843-852 (2007). (Pubitemid 47374140)
6. Chan HL, Wong VW, Tse AM et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin. Gastroenterol. Hepatol. 5, 1462-1468 (2007).
7. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir. Ther. 12, 73-82 (2007).
8. Marcellin P. Hepatitis B and hepatitis C in 2009. Liver Int. 29(Suppl. 1), 1-8 (2009).
9. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J. Hepatol. 50, 227-242 (2009).
10. van Zonneveld M, Honkoop P, Hansen BE et al. Long-term follow-up of α-interferon treatment of patients with chronic hepatitis B. Hepatology 39, 804-810 (2004). (Pubitemid 38337661)
11. Fattovich G, Olivari N, Pasino M, D'Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 57, 84-90 (2008).
12. Moucari R, Korevaar A, Lada O et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J. Hepatol. 50, 1084-1092 (2009).
13. Janssen HL, Kerhof-Los CJ, Heijtink RA, Schalm SW. Measurement of HBsAg to monitor hepatitis B viral replication in patients on α-interferon therapy. Antiviral Res. 23, 251-257 (1994).
14. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 354, 1001-1010 (2006).
15. Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 354, 1011-1020 (2006). (Pubitemid 43357805)
16. Marcellin P, Heathcote EJ, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 359, 2442-2455 (2008).
17. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131, 1743-1751 (2006).
18. Marcellin P, Chang TT, Lim S et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. Hepatology 48, 750-758 (2008).
19. +) chronic hepatitis B: results from study ETV-901. Hepatology (Suppl. S1), 705A (2008).
20. Marcellin P, Lau GK, Bonino F et al. Peginterferon α-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351, 1206-1217 (2004). (Pubitemid 39296307)
21. Lau GK, Piratvisuth T, Luo KX et al. Peginterferon α-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352, 2682-2695 (2005). (Pubitemid 41007823)
22. Buster EH, Flink HJ, Cakaloglu Y et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon α-2b. Gastroenterology 135, 459-467 (2008).
23. Marcellin P, Bonino F, Lau GK et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon α-2a. Gastroenterology 136, 1618-1628 (2009).
24. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 49, S103-S111 (2009).
25. Moucari R, Mackiewicz V, Lada O et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon α-2a in HBeAg-negative patients. Hepatology 49, 1151-1157 (2009).
26. Brunetto MR, Moriconi F, Bonino F et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon α-2a in HBeAg-negative chronic hepatitis B. Hepatology 49, 1141-1150 (2009).
27. Perrillo RP. Hepatitis B surface antigen quantification as a current-day paradox: obtaining the gold in the face of diminishing returns. Hepatology 49, 1063-1065 (2009).